SGLT2 inhibitors and CKD-MBD

In a recent article co-authored by PHD center members: Daniel Hsiang-Te Tsai, Albert Tzu-Ming Chuang, Kuan-Hung Liu, Shih-Chieh Shao, and Edward Chia-Cheng Lai, they investigated the association between SGLT2 inhibitors and biochemical abnormalities related to CKD-MBD. The study found that the use of SGLT2 inhibitors was associated with a lower incidence of CKD-MBD-related biochemical abnormalities compared to GLP-1 receptor agonists. These findings suggest that SGLT2 inhibitors may be considered to reduce the risk of CKD-MBD in patients with type 2 diabetes mellitus and stage 1–3 CKD.